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We reexamined the conditions of tissue disorders resulting from temporary ischemia of the organs as well
as changes in tissue function and the effects on the preservation of renal function over time by using rat
models in order to clinically utilize erythropoietin, which has inhibitory effects on ischemia-reperfusion
disorders.
In 8- to 9-week-old Wister male rats, after the right kidney had been resected under general anesthesia,
the left renal artery was clamped to inhibit the blood flow for 45 minutes. At 30 minutes before inhibiting
the blood flow and after releasing the inhibited blood flow, 100 U/kg of recombinant human erythropoietin
(rhEPO) was administered via the inferior vena cava and the abdominal cavity, and then the tissues and blood
samples were extracted at 6 hours and 24 hours after the release. The renal tissue specimens were evaluated
for apoptosis and renal function using hematoxylin eosin staining and TUNEL staining. Changes in the
emergence of active oxygen were investigated by using blood samples. The degree of renal dysfunction was
evaluated by measuring neutrophil gelatinase-associated lipocalin (NGAL) in the spot urine samples. The
changes in the serum creatinine level, showed that the renal function was preserved with a significant
difference in the rhEPO administration group. The liver deviation enzymes clearly decreased in the rhEPO
administration group. Active oxygen did not change before and after the ischemia-reperfusion nor was it
changed by rhEPO administration. Apoptosis was inhibited by rhEPO administration. No direct effects of
rhEPO administration on the emergence of active oxygen were observed. The administration of rhEPO,
was suggested to help preserve the renal function in marginal donors with a longer agonal stageby effectively.
(Hinyokika Kiyo 56 : 473-479, 2010)
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緒 言
赤血球造血亢進作用を持つ体液成分が1948年に
Bonsdoff ら1) に より erythropoietin と命名され，
Jacobson により erythropoietin は腎で産生されている
ことが明らかにされた7)．Erythropoietin は後期赤芽
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連リポカイン (eutrophil gelatinase-associated lipocain :




からの臓器提供前の死戦期における graft viability 維持
を目的とした erythropoietin の利用可能性に関して Rat
虚血再灌流モデルを用いて検討し提供腎組織障害に対
する biomarker として，スポット尿における NGAL
測定意義を検討した．
対 象 と 方 法
1．Animal model
体重 250∼300 g の Wister/ST 雄ラット32匹を日本
SLC ㈱ (Shizuoka，Japan) より購入し 1週間慣らし飼
いの後実験に使用した．実験遂行にあたっては





reperfusion injury : IRI 群 n＝8) 3．虚血再灌流前30分
rhEPO 投与群 (EPOpre 30群 n＝8），4．虚血再灌流時
rhEPO 投与群 (EPOjust 0群 n＝8）．コントロール
群，EPOpre 30群そして EPOjust 0群には 500 μl の生





べてのラットに対して Diethyl Ether (Wako Pure
Chemical Industries，Ltd Osaka，Japan) にて吸入麻酔
行った後 Sodium Pentbarbital (Kyoritsu Pharm，Ltd












尿素窒素 (BUN），Asparate aminotransferase (AST），




140 μl の 0.1 M NaOAc 緩衝液を加え，次いで血液生
化学検査に利用した血清を検体として 5 μl，また検量
線作成用には過酸化水素水標準液を 5 μl 加えた後，
37°C，5分間インキュベートする．R1* 溶液と R2*





(Reactive oxygen species) 値を算出し対数値で表した．
3．尿中 NGAL 測定 (Sandwich ELISA analysis of




澄を −70°C で使用時まで保存した．NGAL は Strep-
toavidin を用いた Sandwich ELISA analysis の Rat





レートリーダー (model 680 microplate reader，Bio-
* R1 : 0.1 M NaOAc 緩衝液，pH 4.8 に N, N-diethyl-para-
phenylene-diamine，DEPPD) を 100 mg/ml に溶解調整．
R2 : 塩化鉄 (Sigma Aldrich Co，MO，USA) を 0. 1 M
NaOAc 緩衝液に 4.37 mM に溶解調整．
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Rad Laboratories，Inc CA，USA) を用いて 450 nm の
波長で測定しMicroplate Manager Software (ver. 5.2PC，
Japan Bio-Rad Laboratories，Inc Tokyo，Japan) にて解
析を行った．
4．Terminal Deoxynucleotidyltransferase-Mediated dUTP






Apoptosis in situ Detection Kit Wako (Wako Pure
Chemical Industries，Ltd Osaka，Japan) を用い添付の
操作説明に準じて行った．再びエタノールにて多段階
の濃度で脱水処理した後キシレンで透徹処理を行い水
溶性封入剤 (Biomeda Corporation，CA，USA) にて封
入した．顕微鏡観察には Olympus BX50 (OLYMPUS
Corporation，Tokyo，Japan) にて行い，顕微鏡用デジ









































後24時間での TUNEL 染色陽性細胞数を rhEPO 投与
Table 1. The serum creatinine level, urea nitrogen, and liver deviation enzyme level before and after ischemia-
reperfusion in each group
Group
Pre IRI Post IRI 24 hr
Cr (mg/dl) BUN (mg/dl) AST (U/L) ALT (U/L) Cr (mg/dl) BUN (mg/dl) AST (U/L) ALT (U/L)
Control (NS) 0.18 10.2 130.8 53.8 0.22 18.0 146.6 114
IRI (EPO−) 0.26 15.5 127.7 63.9 1.18 74.7 316.1 125.5
IRI (EPO＋pre 30) 0.23 15.3 201.7 84.6 0.54 32.9 257 104.8
IRI (EPO＋just 0) 0.33 17.7 123.5 92.5 1.02 36.9 392 143.8
IRI : Ischemic reperfusion injury, EPO : erythropoietin.
泌56,08,11-1
Fig. 1. Changes in the serum creatinine levels at 6
hours and 24 hours after ischemia-
reperfusion in each group.
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群と非投与群とで比較した．実際，虚血再灌流障害モ
デルでの腎組織は apoptosis を起こした細胞が尿細管




Group pre IRI Postiri 6 hr
IRI (EPO＋pre 30) 159.3 126
IRI (EPO＋just 0) 155 137.8
IRI (EPO−) 146.5 118.3 (unit)
Fig. 2. The serum active oxygen levels at 6 hours
before and after ischemia-reperfusion.
Serum active oxygen was measured with the
total ROS assay system by means of the




Fig. 4. TUNEL staining in the renal tissue at 24 hours after ischemia-reperfusion. A : The control group, B :
The group with only ischemia-reperfusion (EPO−), C : The group in which EPO was administered 30
minutes before ischemia-reperfusion (EPO＋ pre 30) and D : The group in which EPO was administered
concurrently with ischemia-reperfusion (EPO＋ just 0).
泌56,08,11-3
Fig. 3. The concentration of NGAL in spot urine
using ELISA. Urine NGAL before and 6
hours and 24 hours after ischemia-
reperfusion between the group without EPO
administration and the group that received
administration 30 minutes before the
ischemia-reperfusion as compared to the
control group. *P ＜0.05 vs the group
without EPO administration.












ず，虚血と同時に rhEPO を投与した群では rhEPO 投
与なし群と同様腎機能の悪化進行が確認された．
rhEPO の組織障害からの保護機序は直接作用として
腎組織で glutathione peroxydase 活性を亢進させ，HO-
1 (heme oxygenase-1) の産生を促し細胞内酸化ストレ
スを抑制することで組織保護的に働くとされ9)，また
間接的には rhEPO は骨髄において血管内皮前駆細胞
(endothelial progenitor cell ; EPC) 誘導能を示し生理活
















rhEPO のもう 1つの注目すべき点は apoptosis 抑制
効果である．虚血による apoptosis への変化を抑制す
















(Hypoxia inducible facter1-α) によって活性化される分
子の一員として，造血作用以外に低酸素から生じる障

















Fig. 5. The number of positive cells in TUNEL
staining at 6 hours and 24 hours after
ischemia-reperfusion. The number of posi-
tive nuclear staining cells in TUNEL stain-
ing was shown as the average value from
three viewpoints in the control group, the
group without ischemia-reperfusion and
EPO administration (EPO−), the group in
which EPO was administered 30 minutes
before ischemia-reperfusion (EPO＋ pre 30),
and the group in which EPO was admini-
stered concurrently with ischemia-reper-
fusion (EPO＋ just 0).








腎癌細胞は EPO 受容体を発現しているため，EPO が




















ける腎の real time biomarker として利用できる可能性
が示唆された．今後死戦期の長いマージナルドナーで
の rhEPO による marginal graft 保護が臨床利用できる
ようさらに検討を継続する．
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